considering the excellent tolerance coupled with an objective response observed in 34.5 % of the patients , the combination therapy with flutamide and castration ( surgical or lhrh agonist ) appears to be the treatment of choice for prostate cancer patients in relapse after standard endocrine therapy .
C0007344
castration
C0014136
endocrine